SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2840
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice ; volume:17 ; number:1 ; day:27 ; month:4 ; year:2018 ; pages:1-14 ; date:12.2018
Cardiovascular diabetology ; 17, Heft 1 (27.4.2018), 1-14, 12.2018
- Urheber
-
Lee, Dustin M.
- Beteiligte Personen und Organisationen
-
Battson, Micah L.
Jarrell, Dillon K.
Hou, Shuofei
Ecton, Kayl E.
Weir, Tiffany L.
Gentile, Christopher L.
SpringerLink (Online service)
- DOI
-
10.1186/s12933-018-0708-x
- URN
-
urn:nbn:de:101:1-2018070114401588144821
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lee, Dustin M.
- Battson, Micah L.
- Jarrell, Dillon K.
- Hou, Shuofei
- Ecton, Kayl E.
- Weir, Tiffany L.
- Gentile, Christopher L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Acute antiarrhythmic effects of SGLT2 inhibitors–dapagliflozin lowers the excitability of atrial cardiomyocytes
Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy
Dapagliflozin targets SGLT2/SIRT1 signaling to attenuate the osteogenic transdifferentiation of vascular smooth muscle cells
Dapagliflozin
Die Auswirkung der SGLT2-Transporter Inhibition durch Dapagliflozin auf den Natriumgehalt des Gewebes im menschlichen Körper
The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease
A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats
SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling
Untersuchung der therapeutischen Effekte eines Interleukin-1β-Antikörpers und des SGLT2-Inhibitors Dapagliflozin auf den druckbelasteten rechten Ventrikel im Mausmodell
Acute antiarrhythmic effects of SGLT2 inhibitors–dapagliflozin lowers the excitability of atrial cardiomyocytes
Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy
Dapagliflozin targets SGLT2/SIRT1 signaling to attenuate the osteogenic transdifferentiation of vascular smooth muscle cells
Dapagliflozin
Die Auswirkung der SGLT2-Transporter Inhibition durch Dapagliflozin auf den Natriumgehalt des Gewebes im menschlichen Körper
The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease
A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats
SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling
Untersuchung der therapeutischen Effekte eines Interleukin-1β-Antikörpers und des SGLT2-Inhibitors Dapagliflozin auf den druckbelasteten rechten Ventrikel im Mausmodell
Acute antiarrhythmic effects of SGLT2 inhibitors–dapagliflozin lowers the excitability of atrial cardiomyocytes
Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy
Dapagliflozin targets SGLT2/SIRT1 signaling to attenuate the osteogenic transdifferentiation of vascular smooth muscle cells
Dapagliflozin
Die Auswirkung der SGLT2-Transporter Inhibition durch Dapagliflozin auf den Natriumgehalt des Gewebes im menschlichen Körper
The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease
A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats
SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling